| Overview |
| bs-15569R |
| IGFBPL1 Polyclonal Antibody |
| ELISA, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat, Dog, Cow, Sheep, Pig, Horse |
| Specifications |
| Unconjugated |
| Rabbit |
| KLH conjugated synthetic peptide derived from human IGFBPL1 |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles. |
| Target |
| Secreted |
| bA113O24.1; IGFBP-related protein 10; IGFBP-RP4; IGFBPRP4; insulin-like growth factor binding protein related protein 4; insulin-like growth factor-binding protein-like 1; IBPL1_HUMAN; insulin-like growth factor-binding-related protein 4. |
| IGFBPL1 is a secreted IGF (Insulin-like growth factor) binding protein that is known to contain an Ig-like C2-type (immunoglobulin-like) domain, an IGFBP N-terminal domain and a Kazal-like domain. IGF-binding proteins characteristically act to extend the half-life of IGFs and may influence the growth promoting effects of the IGFs. The interaction of IGFBPs with IGFs can affect cell surface receptors, specifically, IGFBPs may enhance or decrease a cells insulin sensitivity. IGFBPL1 has been found to be down-regulated in multiple tumors and thus may be a likely tumor suppressor candidate. Highly expressed in both brain and testis, IGFBPL1 is found at lower levels in the prostate, bladder and lung. |
| Application Dilution |
| ELISA |
1:500-1000 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz